FDA Approves Wayrilz FDA Approves Wayrilz (rilzabrutinib) for Immune Thrombocytopenia
FDA Approves Wayrilz FDA Approves Wayrilz (rilzabrutinib) for Immune Thrombocytopenia

FDA Approves Wayrilz FDA Approves Wayrilz (rilzabrutinib) for Immune Thrombocytopenia
Many Preschoolers Receive ADHD Medications Within 30 Days of Diagnosis
FDA Approves Leqembi Iqlik FDA Approves Leqembi Iqlik (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimers Disease
Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
FDA Approves Novartis Radioligand Therapy Pluvicto for Earlier Use Before Chemotherapy in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer Basel, March 28, 2025 – Novartis announced today that the US Food and Drug Administration (FDA) approv
FDA Approves Vykat XR (diazoxide choline) to Treat Hyperphagia in Prader-Willi Syndrome